2 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
December 31, | 2023 | 2022 | 2021 | Cash flows from operating activities: | Net loss attributable to ordinary shareholders | $ | (208,383) | $ | (148,839) | $ | (142,096) | Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization | 6,565 | 7,422 | 8,458 | Loss on disposal of property and equipment | 3,791 | 515 | 672 | Share-based compensation net of amounts capitalized | 11,204 | 12,014 | 9,937 | Interest expense accrued on liability related to future royalties and sales milestones, net and cumulative catch-up adjustment | 44,999 | 8,884 | 1,093 | Foreign exchange differences | (7,604) | 3,996 | — | Non-cash operating lease expense | 4,058 | 3,432 | 3,728 | Loss on lease incentive and reassessment | — | — | 9 | Loss on termination of operating lease | 95 | — | — | Impairment of operating lease right-of-use assets and related property and equipment | 382 | — | — | Deferred income tax | (986) | (268) | (72) | Changes in operating assets and liabilities | Decrease (increase) in prepaid expenses and other current assets | 10,695 | (10,962) | 5,574 | Decrease in prepaid expenses and other non-current assets | 1,726 | 161 | 503 | Decrease (increase) in long-term deposits | 937 | (5) | 575 | (Decrease) increase in accounts payable | (509) | 22 | (1,816) | (Decrease) increase in accrued expenses and other liabilities | 998 | 16,007 | (2,021) | (Decrease) increase in operating lease liability | (13,555) | (4,687) | (2,405) | Net cash used in operating activities | (145,587) | (112,308) | (117,861) | Cash flows from investing activities: | Purchases of property and equipment | (10,986) | (10,841) | (8,857) | Net cash used in investing activities | (10,986) | (10,841) | (8,857) | Cash flows from financing activities: | Proceeds of issuance of ordinary shares | — | 163,854 | 245,900 | Proceeds from exercise of share options | 27 | 117 | 125 | Proceeds from liability related to future royalties and sales milestones, net | — | 70,000 | 50,000 | Payments of equity issuance costs | (910) | (10,361) | (11,453) | Payments of issuance costs related to the liability related to the sale of future royalties and sales milestones, net | — | — | (509) | Net cash (used in) provided by financing activities | (883) | 223,610 | 284,063 | Effect of exchange rate changes on cash, cash equivalents and restricted cash | 15,030 | (28,376) | (754) | Net (decrease) increase in cash, cash equivalents and restricted cash | (142,426) | 72,085 | 156,591 | Cash, cash equivalents and restricted cash, beginning of period | 382,761 | 310,676 | 154,085 | Cash, cash equivalents and restricted cash, end of period | $ | 240,335 | $ | 382,761 | $ | 310,676 |
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
4.4 | Warrant issued to BXLS V – Autobahn L.P. dated November 6, 2021. | Form 6-K | 001-38547 | 99.3 | 11/8/21 | ||||||||||||||||||||||||||||||
10.1†# | Supply Agreement, dated as of March 23, 2018, by and between the registrant and Miltenyi Biotec GmbH. | Form F-1/A | 333-224720 | 10.2 | 6/8/18 | ||||||||||||||||||||||||||||||
10.2†# | Autolus Therapeutics plc 2018 Equity Incentive Plan. | Form F-1/A | 333-224720 | 10.3 | 6/19/18 | ||||||||||||||||||||||||||||||
10.3+ | Non-employee Sub Plan to the Autolus Therapeutics plc 2018 Equity Incentive Plan. | Form F-1/A | 333-224720 | 10.4 | 6/19/18 | ||||||||||||||||||||||||||||||
10.4+ | Management Incentive Compensation Plan. | Form F-1/A | 333-224720 | 10.5 | 6/8/18 | ||||||||||||||||||||||||||||||
10.5+ | Form of Deed of Indemnity between the registrant and each of its members of senior management and directors. | Form F-1/A | 333-224720 | 10.6 | 6/8/18 | ||||||||||||||||||||||||||||||
10.6†#* | License Agreement, dated as of September 25, 2014 by and between the registrant and UCL Business Ltd., as amended on March 2, 2016, March 28, 2018. | Form F-1/A | 333-224720 | 10.1 | 6/8/18 | ||||||||||||||||||||||||||||||
10.7†#* | Amendment to License Agreement, dated as of September 25, 2014 by and between the registrant and UCL Business Ltd., dated as of October 15, 2020. | Form F-1/A | 001-38547 | 4.7 | 3/4/21 | ||||||||||||||||||||||||||||||
10.8 | Autolus Therapeutics plc, Registration Rights Agreement, dated as June 26, 2018 | Form 20-F | 001-38547 | 2.3 | 11/23/18 | ||||||||||||||||||||||||||||||
10.9 | Collaboration and Financing Agreement, dated as of November 6, 2021, between Autolus Limited and BXLS V — Autobahn L.P. | Form 20-F | 001-38547 | 4.7 | 3/10/22 | ||||||||||||||||||||||||||||||
10.10 | Securities Purchase Agreement by and between the Registrant and BXLS V – Autobahn L.P. dated November 6, 2021. | Form 6-K | 001-38547 | 99.1 | 11/8/21 | ||||||||||||||||||||||||||||||
10.11 | Registration Rights Agreement by and between the Registrant and BXLS V – Autobahn L.P. dated November 6, 2021. | Form 6-K | 001-38547 | 99.2 | 11/8/21 | ||||||||||||||||||||||||||||||
10.12*†# | License and Option Agreement between the registrant and BioNTech SE, dated February 6, 2024. | 10.13 | Securities Purchase Agreement between the registrant and BioNTech SE, dated February 6, 2024. | Form 8-K | 001-38547 | 10.1 | 2/8/24 | ||||||||||||||||||||||||||||
10.14 | Registration Rights Agreement between the registrant and BioNTech SE, dated February 6, 2024. | Form 8-K | 001-38547 | 10.2 | 2/8/24 | ||||||||||||||||||||||||||||||
10.15 | Letter Agreement between the registrant and BioNTech SE, dated February 6, 2024. | Form 8-K | 001-38547 | 10.3 | 2/8/24 | ||||||||||||||||||||||||||||||
10.16† | Lease Agreement, dated September 19, 2023, between Forge Life Sciences Nominee I Limited and Forge Life Sciences Nominee 2 Limited, Autolus Limited and Autolus Therapeutics plc relating to The Nucleus Marshgate, Stevenage. | Form 10-Q | 001-38547 | 10.1 | 11/9/23 | ||||||||||||||||||||||||||||||
10.17† | Amendment 2 to Supply Agreement, dated as of September 27, 2023, by and between Autolus Limited and Miltenyi Biotec B.V. & Co. KG. | Form 10-Q | 001-38547 | 10.2 | 11/9/23 | ||||||||||||||||||||||||||||||
21.1* | Subsidiaries of the registrant. | 23.1* | Consent of Ernst & Young LLP, independent registered public accounting firm |
- Prev
- 1
- Next